Trials / Completed
CompletedNCT00428246
Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation
Anti-Inflammatory and Endothelial Protectant Effects of Paricalcitol
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Indiana University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is about possible protective effects of paricalcitol (Zemplar) upon inflammation, blood pressure and kidney function. Kidney Inflammation occurs when white blood cells become abnormally stimulated and accumulate in the kidney and cause damage to the kidney. The purpose of this study is to determine if paricalcitol helps improve kidney injury, blood pressure control and kidney function in patients with chronic kidney disease. The study will last about 7 weeks and involves about 8 visits to the medical center.
Detailed description
We hypothesize that use of paricalcitol in patients with chronic kidney disease will lead to improvement in oxidative stress, inflammation, endothelial function and subsequently ambulatory blood pressures and glomerular filtration rate. We will pursue our hypothesis by the three specific aims: Aim 1: To compare oxidative stress markers in patients treated with paricalcitol before and after the study. Aim 2: To measure endothelial function by flow mediated dilation in patients with chronic kidney disease before and after paricalcitol. Aim 3: To measure actigraphy guided ambulatory blood pressure and GFR in the absence of changes in anti-hypertensive medications in patients with chronic kidney disease. The study will be double blind randomized pilot trial in 24 patients with chronic kidney disease with 1:1:1 allocation to paricalcitol 1 microgram: paricalcitol 2 microgram: Placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paricalcitol | 1 mcg or 2 mcg for 4 weeks. |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2007-01-29
- Last updated
- 2009-06-03
- Results posted
- 2009-06-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00428246. Inclusion in this directory is not an endorsement.